26.06 USD
-0.45 (-1.7%)
26.06 USD
0 (0%)
PCRX gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. While PCRX belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. PCRX is cheap, but on the other hand it scores bad on growth. With these ratings, PCRX could be worth investigating further for value investing!.
1. Profitability
1.1 Basic Checks
In the past year PCRX was profitable.
In the past year PCRX had a positive cash flow from operations.
Of the past 5 years PCRX 4 years were profitable.
In the past 5 years PCRX always reported a positive cash flow from operatings.
1.2 Ratios
PCRX's Return On Assets of 1.65% is amongst the best of the industry. PCRX outperforms 81.15% of its industry peers.
PCRX's Return On Equity of 2.95% is amongst the best of the industry. PCRX outperforms 82.20% of its industry peers.
The Return On Invested Capital of PCRX (3.63%) is better than 81.68% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for PCRX is significantly below the industry average of 12.85%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.65% | ||
| ROE | 2.95% | ||
| ROIC | 3.63% |
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.3%
ROIC(5y)4.55%
1.3 Margins
Looking at the Profit Margin, with a value of 2.99%, PCRX is in the better half of the industry, outperforming 79.58% of the companies in the same industry.
PCRX's Operating Margin of 8.88% is amongst the best of the industry. PCRX outperforms 81.15% of its industry peers.
PCRX's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 79.17%, PCRX belongs to the top of the industry, outperforming 84.29% of the companies in the same industry.
In the last couple of years the Gross Margin of PCRX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.88% | ||
| PM (TTM) | 2.99% | ||
| GM | 79.17% |
OM growth 3Y-15.96%
OM growth 5Y11.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PCRX is destroying value.
Compared to 1 year ago, PCRX has less shares outstanding
Compared to 5 years ago, PCRX has more shares outstanding
PCRX has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.12 indicates that PCRX is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.12, PCRX is in line with its industry, outperforming 57.07% of the companies in the same industry.
PCRX has a debt to FCF ratio of 3.03. This is a good value and a sign of high solvency as PCRX would need 3.03 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 3.03, PCRX belongs to the best of the industry, outperforming 90.05% of the companies in the same industry.
PCRX has a Debt/Equity ratio of 0.52. This is a neutral value indicating PCRX is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.52, PCRX is doing worse than 63.35% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 3.03 | ||
| Altman-Z | 2.12 |
ROIC/WACC0.45
WACC8.04%
2.3 Liquidity
A Current Ratio of 5.26 indicates that PCRX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.26, PCRX is in the better half of the industry, outperforming 64.40% of the companies in the same industry.
PCRX has a Quick Ratio of 3.78. This indicates that PCRX is financially healthy and has no problem in meeting its short term obligations.
PCRX has a Quick ratio (3.78) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.26 | ||
| Quick Ratio | 3.78 |
3. Growth
3.1 Past
PCRX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.90%.
Measured over the past years, PCRX shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.96% on average per year.
PCRX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -16.85%.
Measured over the past years, PCRX shows a quite strong growth in Revenue. The Revenue has been growing by 10.73% on average per year.
EPS 1Y (TTM)-6.9%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-11.39%
Revenue 1Y (TTM)-16.85%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%6.49%
3.2 Future
Based on estimates for the next years, PCRX will show a small growth in Earnings Per Share. The EPS will grow by 7.17% on average per year.
The Revenue is expected to grow by 6.09% on average over the next years.
EPS Next Y-5.84%
EPS Next 2Y4.39%
EPS Next 3Y6.17%
EPS Next 5Y7.17%
Revenue Next Year4.36%
Revenue Next 2Y6.92%
Revenue Next 3Y7.35%
Revenue Next 5Y6.09%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 8.77, the valuation of PCRX can be described as reasonable.
92.15% of the companies in the same industry are more expensive than PCRX, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 26.84. PCRX is valued rather cheaply when compared to this.
Based on the Price/Forward Earnings ratio of 7.45, the valuation of PCRX can be described as very cheap.
91.10% of the companies in the same industry are more expensive than PCRX, based on the Price/Forward Earnings ratio.
PCRX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.40.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.77 | ||
| Fwd PE | 7.45 |
4.2 Price Multiples
PCRX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. PCRX is cheaper than 91.62% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of PCRX indicates a rather cheap valuation: PCRX is cheaper than 92.67% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.03 | ||
| EV/EBITDA | 7.58 |
4.3 Compensation for Growth
The decent profitability rating of PCRX may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.63
EPS Next 2Y4.39%
EPS Next 3Y6.17%
5. Dividend
5.1 Amount
No dividends for PCRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
26.06
-0.45 (-1.7%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners114.07%
Inst Owner Change-5.56%
Ins Owners0.79%
Ins Owner Change-1.27%
Market Cap1.12B
Revenue(TTM)716.79M
Net Income(TTM)21.44M
Analysts76.92
Price Target30.31 (16.31%)
Short Float %17.11%
Short Ratio10.26
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.71%
Min EPS beat(2)2.13%
Max EPS beat(2)5.28%
EPS beat(4)4
Avg EPS beat(4)4.05%
Min EPS beat(4)1.99%
Max EPS beat(4)6.81%
EPS beat(8)6
Avg EPS beat(8)5.89%
EPS beat(12)7
Avg EPS beat(12)1.4%
EPS beat(16)8
Avg EPS beat(16)-3.85%
Revenue beat(2)0
Avg Revenue beat(2)-3.29%
Min Revenue beat(2)-3.59%
Max Revenue beat(2)-2.99%
Revenue beat(4)0
Avg Revenue beat(4)-3.23%
Min Revenue beat(4)-5.92%
Max Revenue beat(4)-0.42%
Revenue beat(8)1
Avg Revenue beat(8)-2.14%
Revenue beat(12)1
Avg Revenue beat(12)-2.68%
Revenue beat(16)1
Avg Revenue beat(16)-2.53%
PT rev (1m)-19.69%
PT rev (3m)-20.55%
EPS NQ rev (1m)0.97%
EPS NQ rev (3m)6.1%
EPS NY rev (1m)3.18%
EPS NY rev (3m)4.05%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.09%
Revenue NY rev (1m)-0.96%
Revenue NY rev (3m)-1.04%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.77 | ||
| Fwd PE | 7.45 | ||
| P/S | 1.56 | ||
| P/FCF | 9.03 | ||
| P/OCF | 7.93 | ||
| P/B | 1.54 | ||
| P/tB | 3.45 | ||
| EV/EBITDA | 7.58 |
EPS(TTM)2.97
EY11.4%
EPS(NY)3.5
Fwd EY13.42%
FCF(TTM)2.89
FCFY11.08%
OCF(TTM)3.29
OCFY12.62%
SpS16.66
BVpS16.9
TBVpS7.54
PEG (NY)N/A
PEG (5Y)0.63
Graham Number33.61
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.65% | ||
| ROE | 2.95% | ||
| ROCE | 5.34% | ||
| ROIC | 3.63% | ||
| ROICexc | 4.58% | ||
| ROICexgc | 7.99% | ||
| OM | 8.88% | ||
| PM (TTM) | 2.99% | ||
| GM | 79.17% | ||
| FCFM | 17.33% |
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.3%
ROIC(5y)4.55%
ROICexc(3y)6.05%
ROICexc(5y)7.29%
ROICexgc(3y)13.64%
ROICexgc(5y)24.93%
ROCE(3y)6.32%
ROCE(5y)6.69%
ROICexgc growth 3Y-33.29%
ROICexgc growth 5Y14.33%
ROICexc growth 3Y-3.13%
ROICexc growth 5Y10.2%
OM growth 3Y-15.96%
OM growth 5Y11.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
F-Score7
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 3.03 | ||
| Debt/EBITDA | 2.44 | ||
| Cap/Depr | 18.95% | ||
| Cap/Sales | 2.4% | ||
| Interest Coverage | 4.07 | ||
| Cash Conversion | 91.52% | ||
| Profit Quality | 579.36% | ||
| Current Ratio | 5.26 | ||
| Quick Ratio | 3.78 | ||
| Altman-Z | 2.12 |
F-Score7
WACC8.04%
ROIC/WACC0.45
Cap/Depr(3y)22.15%
Cap/Depr(5y)83.49%
Cap/Sales(3y)2.76%
Cap/Sales(5y)5.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.9%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-11.39%
EPS Next Y-5.84%
EPS Next 2Y4.39%
EPS Next 3Y6.17%
EPS Next 5Y7.17%
Revenue 1Y (TTM)-16.85%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%6.49%
Revenue Next Year4.36%
Revenue Next 2Y6.92%
Revenue Next 3Y7.35%
Revenue Next 5Y6.09%
EBIT growth 1Y-45.68%
EBIT growth 3Y-8.41%
EBIT growth 5Y23.37%
EBIT Next Year1.52%
EBIT Next 3Y6.95%
EBIT Next 5Y6.85%
FCF growth 1Y-4.68%
FCF growth 3Y30.84%
FCF growth 5Y24.28%
OCF growth 1Y-5.2%
OCF growth 3Y14.64%
OCF growth 5Y21.85%
PACIRA BIOSCIENCES INC / PCRX FAQ
What is the ChartMill fundamental rating of PACIRA BIOSCIENCES INC (PCRX) stock?
ChartMill assigns a fundamental rating of 6 / 10 to PCRX.
What is the valuation status of PACIRA BIOSCIENCES INC (PCRX) stock?
ChartMill assigns a valuation rating of 8 / 10 to PACIRA BIOSCIENCES INC (PCRX). This can be considered as Undervalued.
How profitable is PACIRA BIOSCIENCES INC (PCRX) stock?
PACIRA BIOSCIENCES INC (PCRX) has a profitability rating of 7 / 10.
What are the PE and PB ratios of PACIRA BIOSCIENCES INC (PCRX) stock?
The Price/Earnings (PE) ratio for PACIRA BIOSCIENCES INC (PCRX) is 8.77 and the Price/Book (PB) ratio is 1.54.
What is the financial health of PACIRA BIOSCIENCES INC (PCRX) stock?
The financial health rating of PACIRA BIOSCIENCES INC (PCRX) is 6 / 10.